However, our study focused specifically on assessing the Duo-assay’s ability to differentiate between individuals with active infection (anti-HCV+ and Duo/HCVcAg +) and those with resolved infection (anti-HCV+ and Duo/HCVcAg–). This evidence concerns the gene KALRN and infection.